-
The role of M1/M2 macrophage polarization in primary Sjogren’s syndrome Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-05-14 Xiaochan Chen, Linjiang Zhu, Huaxiang Wu
The purpose of this study was to investigate the role of macrophage polarization in the pathogenesis of primary Sjogren’s syndrome (pSS). Peripheral venous blood samples were collected from 30 patients with pSS and 30 healthy controls. Minor salivary gland samples were abtainted from 10 of these patients and 10 non-pSS controls whose minor salivary gland didn’t fulfill the classification criteria for
-
Can the Dose of Belimumab be Reduced in Patients with Systemic Lupus Erythematosus? Rheumatology (IF 5.5) Pub Date : 2024-05-14 Iñigo Rua-Figueroa, I Altabás-González, C Mouriño, K Roberts, A Hernández-Martín, I Casafont-Solé, J Font-Urgelles, J A Román-Ivorra, M de la Rubia Navarro, M Galindo-Izquierdo, T C Salman-Monte, J Narváez, P Vidal-Montal, M J García-Villanueva, S Garrote-Corral, M A Blazquez- Canamero, Carlos Marras Fernandez-Cid, M Piqueras-García, J Martínez-Barrio, M Sánchez-Lucas, J Cortés-Hernández, E Penzo
Objectives The aims of this study were to investigate the prevalence of dose reduction in patients with SLE treated with belimumab (BEL) in Spain, analyze treatment modalities, and determine impact on control of disease activity. Methods Retrospective longitudinal and multicentre study of SLE patients treated with BEL. Data on disease activity, treatments and outcomes were recorded before and after
-
Recent advancements in cartilage tissue engineering innovation and translation Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-05-13 Rachel C. Nordberg, Benjamin J. Bielajew, Takumi Takahashi, Shuyan Dai, Jerry C. Hu, Kyriacos A. Athanasiou
-
Identification and verification of a novel signature that combines cuproptosis-related genes with ferroptosis-related genes in osteoarthritis using bioinformatics analysis and experimental validation Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-05-13 Baoqiang He, Yehui Liao, Minghao Tian, Chao Tang, Qiang Tang, Fei Ma, Wenyang Zhou, Yebo Leng, Dejun Zhong
Exploring the pathogenesis of osteoarthritis (OA) is important for its prevention, diagnosis, and treatment. Therefore, we aimed to construct novel signature genes (c-FRGs) combining cuproptosis-related genes (CRGs) with ferroptosis-related genes (FRGs) to explore the pathogenesis of OA and aid in its treatment. Differentially expressed c-FRGs (c-FDEGs) were obtained using R software. Enrichment analysis
-
Unraveling transcriptomic signatures and dysregulated pathways in systemic lupus erythematosus across disease states Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-05-13 Frank Qingyun Wang, Li Shao, Xiao Dang, Yong-Fei Wang, Shuxiong Chen, Zhongyi Liu, Yujing Mao, Yuping Jiang, Fei Hou, Xianghua Guo, Jian Li, Lili Zhang, Yuting Sang, Xuan Zhao, Ruirui Ma, Kai Zhang, Yanfang Zhang, Jing Yang, Xiwu Wen, Jiong Liu, Wei Wei, Chuanpeng Zhang, Weiyang Li, Xiao Qin, Yao Lei, Hong Feng, Xingtian Yang, Chun Hing She, Caicai Zhang, Huidong Su, Xinxin Chen, Jing Yang, Yu Lung
This study aims to elucidate the transcriptomic signatures and dysregulated pathways in patients with Systemic Lupus Erythematosus (SLE), with a particular focus on those persisting during disease remission. We conducted bulk RNA-sequencing of peripheral blood mononuclear cells (PBMCs) from a well-defined cohort comprising 26 remission patients meeting the Low Lupus Disease Activity State (LLDAS) criteria
-
Validation of the Behçet’s Syndrome Overall Damage Index (BODI) for Retrospective Studies and a Proposal for Modification Rheumatology (IF 5.5) Pub Date : 2024-05-11 Yeliz Yagiz Ozogul, Yesim Ozguler, Sinem N Esatoglu, Didar Ucar, Ugur Uygunoglu, Zekayi Kutlubay, Vedat Hamuryudan, Gulen Hatemi
Objective Assessment of damage accrual over time is important for evaluating and comparing long-term results of treatment modalities and strategies. Retrospective studies may be useful for assessing long-term damage, especially in rare diseases. We aimed to validate Behçet’s Syndrome Overall Damage Index (BODI) for use in retrospective studies by evaluating its construct validity, reliability, and
-
Risk of urolithiasis associated with allopurinol versus benzbromarone among patients with gout: a population-based cohort study Rheumatology (IF 5.5) Pub Date : 2024-05-11 Eun Ha Kang, Anna Shin, Chang Soo Park, Eun Bong Lee, Yun Jong Lee, Gary Curhan, Hyon K Choi
Objectives To compare the risk of urolithiasis in gout patients initiating allopurinol, a xanthine oxidase inhibitor, vs benzbromarone, a uricosuric. Methods Using the 2011–2020 Korea National Health Insurance Service database, we conducted a cohort study on gout patients initiating allopurinol vs benzbromarone as the 1st-line urate-lowering treatment (ULT). The primary outcome was a new onset urinary
-
Efficacy and safety study of targeted small-molecule drugs in the treatment of systemic lupus erythematosus Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-05-10 Shiheng Wang, Wanling Ning, Hanqing Tang, Chaochao Mu, Xiaosong Huang
Targeted small-molecule drugs in the treatment of systemic lupus erythematosus (SLE) have attracted increasing attention from clinical investigators. However, there is still a lack of evidence on the difference in the efficacy and safety of different targeted small-molecule drugs. Therefore, this study was conducted to assess the efficacy and safety of different targeted small-molecule drugs for SLE
-
Long term use of interleukin-1 inhibitors reduce flare activity in patients with fibrodysplasia ossificans progressiva Rheumatology (IF 5.5) Pub Date : 2024-05-10 Ruby Haviv, Leonid Zeitlin, Veronica Moshe, Amit Ziv, Noa Rabinowicz, Fabrizio De Benedetti, Giusi Prencipe, Valentina Matteo, Carmen Laura De Cunto, Edward C Hsiao, Yosef Uziel
Objectives Fibrodysplasia ossificans progressiva (FOP) is one of the most catastrophic forms of genetic heterotopic ossification (HO). FOP is characterized by severe, progressive inflammatory flare-ups, that often lead to HO. The flare-ups are associated with increased inflammatory cytokine production, suggesting auto-inflammatory features driven by interleukin-1β (IL-1β). This study describes the
-
Predictive factors and treatment outcomes associated with difficult-to-treat rheumatoid arthritis conditions: the ANSWER cohort study Rheumatology (IF 5.5) Pub Date : 2024-05-10 Ryu Watanabe, Kosuke Ebina, Takaho Gon, Tadashi Okano, Koichi Murata, Kosaku Murakami, Yuichi Maeda, Sadao Jinno, Iku Shirasugi, Yonsu Son, Hideki Amuro, Masaki Katayama, Ryota Hara, Kenichiro Hata, Ayaka Yoshikawa, Wataru Yamamoto, Shotaro Tachibana, Shinya Hayashi, Yuki Etani, Masao Katsushima, Kazuo Fukumoto, Shinsuke Yamada, Motomu Hashimoto
Objectives To investigate the predictive factors for difficult-to-treat rheumatoid arthritis (D2T RA) and assess the efficacy of biological disease-modifying antirheumatic drugs (bDMARDs) and Janus kinase inhibitors (JAKi). Methods Retrospective analysis was conducted on data from the ANSWER cohort comprising 3,623 RA patients treated with bDMARDs or JAKi in Japan. Multivariate Cox proportional hazards
-
Arthritis in patients with very early systemic sclerosis: a comprehensive clinical and prognostic analysis Rheumatology (IF 5.5) Pub Date : 2024-05-10 Sinziana Muraru, Carina Mihai, Muriel Elhai, Mike Becker, Suzana Jordan, Alexandru Garaiman, Cosimo Bruni, Liubov Petelytska, Anna-Maria Hoffmann-Vold, Oliver Distler, Rucsandra Dobrota
Objective Arthritis is associated with a worse prognosis in established systemic sclerosis (SSc). However, knowledge about its relevance in very early SSc (veSSc) is scarce. We aimed to assess the prevalence and phenotype of arthritis, as well as its prognostic impact, in patients with veSSc. Methods We analysed patients with veSSc, defined as presence of Raynaud’s phenomenon and/or at least one of:
-
Early identification of macrophage activation syndrome secondary to systemic lupus erythematosus with machine learning Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-05-09 Wenxun Lin, Xi Xie, Zhijun Luo, Xiaoqi Chen, Heng Cao, Xun Fang, You Song, Xujing Yuan, Xiaojing Liu, Rong Du
The macrophage activation syndrome (MAS) secondary to systemic lupus erythematosus (SLE) is a severe and life-threatening complication. Early diagnosis of MAS is particularly challenging. In this study, machine learning models and diagnostic scoring card were developed to aid in clinical decision-making using clinical characteristics. We retrospectively collected clinical data from 188 patients with
-
Optimal exposure of mycophenolic acid for induction therapy of childhood lupus nephritis patients: an observational cohort study Rheumatology (IF 5.5) Pub Date : 2024-05-09 Lu Zhang, Lizhi Chen, Xiaohong Liu, Zhijun Huang, Yifan Zheng, Kejing Tang, Xiaoyun Jiang, Pan Chen
Objectives Mycophenolic acid (MPA) is recommended for lupus nephritis (LN) treatment, but with large inter-individual variability in pharmacokinetics (PK). The aim of this study is to reveal the relationship between MPA exposure and disease response and adverse drug reactions in pediatric LN patients. Method This was a population-based observational cohort study. A total of 86 pediatric LN patients
-
Bone-modifying drugs slow OA progression Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-05-07 Sarah Onuora
Drugs used to treat osteoporosis could slow the progression of osteoarthritis, according to the findings of a study in mice.
-
The OMERACT Giant cell arteritis Ultrasonography Score: a potential predictive outcome to assess the risk of relapse during follow-up Rheumatology (IF 5.5) Pub Date : 2024-05-08 Juan Molina-Collada, Irene Monjo-Henry, Elisa Fernández-Fernández, José María Álvaro-Gracia, Eugenio de Miguel
Objective To determine whether the OMERACT giant cell arteritis (GCA) Ultrasonography (US) Score (OGUS) change after treatment can be used for assessing the probability of relapse. Methods Multicenter retrospective study of GCA patients referred to two US GCA fast-track clinics over 2 years. Patients underwent US evaluation at baseline, 3 and 6 months. EULAR definitions for remission and relapse were
-
Plasma mtDNA as a possible contributor to and biomarker of inflammation in rheumatoid arthritis Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-05-07 Julia Lehmann, Stavros Giaglis, Diego Kyburz, Douglas Daoudlarian, Ulrich A. Walker
Neutrophil extracellular trap formation and cell-free DNA (cfDNA) contribute to the inflammation in rheumatoid arthritis (RA), but it is unknown if mitochondrial DNA (mtDNA) or nuclear DNA (nDNA) is more abundant in the circulation. It is unclear if DNA concentration measurements may assist in clinical decision-making. This single-center prospective observational study collected plasma from consecutive
-
Deficiency of histone deacetylases 3 in macrophage alleviates monosodium urate crystals-induced gouty inflammation in mice Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-05-06 Qi-Bin Yang, Meng-Yun Zhang, Liu Yang, Jie Wang, Qing-Sheng Mi, Jing-Guo Zhou
Gout is caused by monosodium urate (MSU) crystals deposition to trigger immune response. A recent study suggested that inhibition of Class I Histone deacetylases (HDACs) can significantly reduce MSU crystals-induced inflammation. However, which one of HDACs members in response to MSU crystals was still unknown. Here, we investigated the roles of HDAC3 in MSU crystals-induced gouty inflammation. Macrophage
-
Transitioning from pediatric to adult-oriented healthcare in rheumatology: the pediatric side of the coin Rheumatology (IF 5.5) Pub Date : 2024-05-06 Ezgi Deniz Batu, Zeynep Balik, Seher Sener, Emil Aliyev, Yagmur Bayindir, Veysel Cam, Muserref Kasap Cuceoglu, Ummusen Kaya Akca, Levent Kilic, Ozge Basaran, Yelda Bilginer, Sule Apras Bilgen, Seza Ozen
Objectives The transition of adolescents and young adults (AYAs) from pediatric to adult-oriented healthcare may be affected by many factors, including the personal and cultural settings. We aimed to analyze the transition readiness and the factors affecting the transition success in rheumatology. Methods Patients older than 12 years were included in this prospective study. All filled out the Transition
-
A treatment algorithm for familial Mediterranean fever patients with menstruation-associated attacks Rheumatology (IF 5.5) Pub Date : 2024-05-06 Ezgi Deniz Batu, Yagmur Bayindir, Seher Sener, Zeynep Balik, Emil Aliyev, Muserref Kasap Cuceoglu, Ozge Basaran, Yelda Bilginer, Seza Ozen
Objectives Familial Mediterranean fever (FMF) is characterized by febrile polyserositis attacks. Menstruation could be a trigger for attacks. We aimed to analyze the features of adolescent FMF patients with menstruation-associated attacks and propose a management algorithm. Methods All female FMF patients who had menarche and visited the Pediatric Rheumatology Unit between January-December 2022, were
-
Glymphatic abnormality in systemic lupus erythematosus detected by diffusion tensor image analysis along the perivascular space Rheumatology (IF 5.5) Pub Date : 2024-05-06 Jiaying Mo, Kai Han, Kan Deng, Wenjun Hu, Linhui Wang, Jingyi Wang, Yikai Xu, Qin Huang, Xiangliang Tan
Objectives This study aimed to evaluate the activity of the glymphatic system in systemic lupus erythematosus (SLE) by a diffusion-based method termed “Diffusion Tensor Image Analysis aLong the Perivascular Space (DTI-ALPS)”, and examined its correlations with morphological changes in the brain. Methods In this cross-sectional study, forty-five female patients with SLE and thirty healthy controls (HCs)
-
Rheumatoid arthritis disease activity significantly impacts on the severity of interstitial lung disease Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-05-04 Yuhei Ito, Yasutaka Ichikawa, Shuichi Murashima, Hajime Sakuma, Ayako Nakajima
Rheumatoid arthritis (RA) related interstitial lung disease (ILD) impacts on the treatment strategy and its prognosis in patients with RA. However, the relationship between RA disease activity and the severity of comorbid ILD has not been fully investigated. This study aimed to investigate the impact of RA disease activity on the severity of comorbid ILD in detail based on currently established visual
-
Adropin inhibits fibrosis in SSc Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-05-03 Robert Phillips
The peptide hormone adropin, which is downregulated in dermal fibroblasts in patients with systemic sclerosis (SSc), inhibits TGFβ-mediated fibrosis in in vitro and ex vivo models of human skin, and has potential for the treatment of SSc.
-
Rethinking antiphospholipid syndrome to guide future management and research Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-05-03 Jason S. Knight, Doruk Erkan
Antiphospholipid syndrome (APS) consists of thrombotic, non-thrombotic and obstetric clinical manifestations developing in individuals with persistent antiphospholipid antibodies (aPL). Although researchers have made progress in characterizing different clinical phenotypes of aPL-positive people, the current approach to clinical management is still mostly based on a ‘one size fits all’ strategy, which
-
Anti-CX3CL1 (fractalkine) monoclonal antibody attenuates lung and skin fibrosis in sclerodermatous graft-versus-host disease mouse model Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-05-03 Takumi Hasegawa, Akira Utsunomiya, Takenao Chino, Hiroshi Kasamatsu, Tomomi Shimizu, Takashi Matsushita, Takashi Obara, Naoto Ishii, Hideaki Ogasawara, Wataru Ikeda, Toshio Imai, Noritaka Oyama, Minoru Hasegawa
Systemic sclerosis (SSc) is an autoimmune disease characterized by vascular injury and inflammation, followed by excessive fibrosis of the skin and other internal organs, including the lungs. CX3CL1 (fractalkine), a chemokine expressed on endothelial cells, supports the migration of macrophages and T cells that express its specific receptor CX3CR1 into targeted tissues. We previously reported that
-
Clinical features of patients with systemic sclerosis positive for anti-SS-A antibody: a cohort study of 156 patients Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-05-03 Tomoya Watanabe, Yasushi Ototake, Asami Akita, Mao Suzuki, Miwa Kanaoka, Jun Tamura, Yusuke Saigusa, Yukie Yamaguchi
Anti-SS-A/Ro antibody (anti-SSA), the diagnostic marker of Sjögren’s syndrome (SS), is often detected in systemic sclerosis (SSc). Some patients are diagnosed with SSc/SS overlap syndromes, while there are anti-SSA-positive SSc cases without SS. In this study, we investigated the clinical characteristics of SSc with anti-SSA and clarified the clinical impact of this antibody in SSc. A retrospective
-
Risk of gastrointestinal perforation in patients with rheumatic diseases exposed to janus kinase inhibitors versus adalimumab: nationwide cohort study Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-05-03 Lea Hoisnard, Antoine Meyer, Rosemary Dray‐Spira, Alain Weill, Mahmoud Zureik, Emilie Sbidian
-
Paediatric non-infectious granulomatous uveitis: a retrospective cohort study Rheumatology (IF 5.5) Pub Date : 2024-05-03 Ai Tien Nguyen, Antoine Rousseau, Bahram Bodaghi, Linda Rossi-Semerano, Caroline Galeotti, Elodie Da Cunha, Laura Eid, Marc Labetoulle, Emmanuel Barreau, Cherif Titah, Adélaïde Toutée, Isabelle Koné-Paut, Perrine Dusser, Charlotte Borocco
Introduction Paediatric granulomatous uveitis (PGU) is rare. In addition, lack of awareness often leads to delayed diagnosis and poor visual outcome. Identifying the underlying cause and deciding how best to treat each patient is challenging. Objectives To evaluate the demographics, aetiologies, complications, treatments, and visual prognosis of paediatric non-infectious granulomatous uveitis. Methods
-
Relapsing polychondritis: clinical updates and new differential diagnoses Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-05-02 Philippe Mertz, Nathalie Costedoat-Chalumeau, Marcela A. Ferrada, Guillaume Moulis, Arsène Mekinian, Peter C. Grayson, Laurent Arnaud
-
Burton's line and scar hyperpigmentation in a patient with severe lead poisoning and saturnine gout Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-05-02 Gisela Garcia‐Arellano, Maria Fernanda Ortiz‐Nuño, Griselda Serna‐Peña, Juan Pablo Toledo‐Motta, Ana Victoria Vasquez‐Gallegos, Dionicio Angel Galarza‐Delgado, Jesus Alberto Cardenas‐de la Garza
-
Increased prevalence of malignancies in patients with IgG4-related disease: implications for clinical care Rheumatology (IF 5.5) Pub Date : 2024-05-02 Luca Keller-Sarmiento, Naomi Viapiana, Marco Lanzillotta, Veronica Batani, Jasmin Mahajne, Lorenzo Dagna, Emanuel Della-Torre
Objectives The association between cancer and IgG4-related disease (IgG4-RD) is evolving. The primary aim of this study was to investigate the prevalence of malignancies in IgG4-RD. The secondary aim was to describe the epidemiological and clinical characteristics of IgG4-RD patients with a history of cancer. Methods Two hundred and ten patients with IgG4-RD were included in this retrospective study
-
Combination of cytoplasmic and nuclear patterns on Hep-2 antinuclear antibody is useful as a screening test for anti-synthetase syndrome Rheumatology (IF 5.5) Pub Date : 2024-05-02 Katsuyuki Yoshida, Soshi Takahashi, Ryota Kawai, Toshiharu Saito, Saori Hatachi, Ayumi Shintani, Hitoshi Sugawara, Shunichi Kumagai
Objective This study aimed to establish a screening model for differentiating anti-synthetase syndrome (ASS) from other antinuclear antibody (ANA)-associated rheumatic diseases (AARD) using a combination of cytoplasmic and non-cytoplasmic ANA (ncANA) patterns. Methods This retrospective observational study included patients with AARDs such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc)
-
Granzyme serine proteases in inflammation and rheumatic diseases Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-04-30 Alexandre Aubert, Karen Jung, Sho Hiroyasu, Julian Pardo, David J. Granville
-
Interstitial fibrosis increases the risk of end-stage kidney disease in patients with lupus nephritis Rheumatology (IF 5.5) Pub Date : 2024-05-01 Yi-Syuan Sun, De-Feng Huang, Fu-Pang Chang, Wei-Sheng Chen, Hsien-Tzung Liao, Ming-Han Chen, Hung-Cheng Tsai, Ming-Tsun Tsai, Chang-Youh Tsai, Chien-Chih Lai, Chih- Yu Yang
Objective To evaluate the risk of end-stage kidney disease (ESKD) in lupus nephritis (LN) patients using tubulointerstitial lesion scores. Methods Clinical profiles and histopathological presentations of 151 biopsy-proven LN patients were retrospectively examined. Risk factors of ESKD based on characteristics and scoring of their tubulointerstitial lesions (e.g. interstitial inflammation [II], tubular
-
Defining criteria for disease activity states in systemic juvenile idiopathic arthritis based on the systemic Juvenile Arthritis Disease Activity Score Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-04-29 Silvia Rosina, Ana I. Rebollo‐Gimenez, Letizia Tarantola, Angela Pistorio, Yulia Vyzhga, Yasser El Miedany, Hala M. Lotfy, Hend Abu‐Shady, Mervat Eissa, Naglaa S. Osman, Waleed Hassan, Marwa Y. Mahgoub, Nermeen A. Fouad, Doaa M. Mosa, Yasmin Adel, Sheren E. M. Mohamed, Ahmed R. Radwan, Mohamed H. Abu‐Zaid, Samar A. A. Tabra, Radwa H. Shalaby, Samah I. Nasef, Raju Khubchandani, Archana Khan, Naziya
ObjectiveTo develop and validate cutoff values in the systemic Juvenile Arthritis Disease Activity Score 10 (sJADAS10) that distinguish the states of inactive disease (ID), minimal disease activity (MiDA), moderate disease activity (MoDA), and high disease activity (HDA) in children with systemic juvenile idiopathic arthritis (sJIA), based on subjective disease state assessment by the treating pediatric
-
Treat-to-target or treat-to-dissolve strategy to improve gout treatment Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-04-26 Pascal Richette, Nicola Dalbeth
Medication adherence in gout is low, and discontinuation of urate-lowering therapy puts patients at risk of flares and cardiovascular events. A strategy to regularly monitor serum urate levels and the dissolution of urate deposits (particularly if visualized by patients) might encourage adherence in the long term.
-
Thyroid hormone induces ossification and terminal maturation in a preserved OA cartilage biomimetic model Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-04-25 N. M. Korthagen, E. Houtman, I. Boone, R. Coutinho de Almeida, K. Sivasubramaniyan, R. Mahdad, R. G. H. H Nelissen, Y. F. M. Ramos, M. A Tessari, I. Meulenbelt
To characterize aspects of triiodothyronine (T3) induced chondrocyte terminal maturation within the molecular osteoarthritis pathophysiology using the previously established T3 human ex vivo osteochondral explant model. RNA-sequencing was performed on explant cartilage obtained from OA patients (n = 8), that was cultured ex vivo with or without T3 (10 ng/ml), and main findings were validated using
-
Sex-specific disparities in disease activity scores among patients with axial spondyloarthritis and their implications for evaluating the response to tumor necrosis factor alpha inhibitor therapy Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-04-25 Seulkee Lee, Seonyoung Kang, Hyungjin Kim, Jaejoon Lee, Min-Ji Kim, Hoon-Suk Cha
We aimed to investigate whether there are sex differences in disease activity measures among patients with axial spondyloarthritis (axSpA) and to determine any potential impact on the assessment of treatment responses to tumor necrosis factor alpha inhibitors (TNFi). Using the Korean College of Rheumatology Biologics and Targeted Therapy (KOBIO) registry data, we compared sex differences in changes
-
-
-
-
-
E050 Angiotensin converting enzyme for the diagnosis of childhood sarcoidosis Rheumatology (IF 5.5) Pub Date : 2024-04-24 Madeleine C Mackay, Samundeeswari Deepak, Kishore Warrier, Satyapal Rangaraj
Background/Aims Childhood sarcoidosis is a rare multisystem inflammatory granulomatous disease. The prevalence of sarcoidosis in children is unknown due to its rarity. A review of sarcoidosis in Denmark found an incidence in children < 15 years of 0.22-0.27 per 100 000/year. Diagnosis can be challenging given the varied presentations due to multisystem involvement. There is no one laboratory test that
-
P187 Fatigue in people with polymyalgia rheumatica: a key unmet need? Rheumatology (IF 5.5) Pub Date : 2024-04-24 Sara Muller, John Belcher, Samantha Hider, Toby Helliwell, Christian D Mallen
Background/Aims Polymyalgia rheumatica (PMR) is common in older adults, causing severe pain and stiffness, particularly in the shoulder and hip girdles. Glucocorticoids treatment generally focusses on reducing pain and stiffness, but there are other aspects to quality of life. Fatigue is a well-recognised symptom in other inflammatory rheumatological conditions and has been highlighted by people with
-
OA04 Efficacy and safety of nipocalimab in patients with moderate to severe active rheumatoid arthritis: the multicenter, randomised, double-blinded, placebo-controlled phase 2a IRIS-RA study Rheumatology (IF 5.5) Pub Date : 2024-04-24 Peter C Taylor, George Schett, Fowzia Ibrahim, Bei Zhou, Jocelyn Leu, Sophia Liva, Quingmin Wang, Ricardo Rojo Cella, Chetan S Karyekar, Kaiyin Fei
Background/Aims Rheumatoid arthritis (RA) is a chronic inflammatory disease associated with autoantibodies. Despite the use of targeted therapies, up to half of patients fail to achieve remission or low disease activity (LDA). Anti-citrullinated protein antibodies (ACPAs), key autoantibodies that predict progression of joint destruction in RA, are largely an immunoglobulin G (IgG) isotype. Nipocalimab
-
E041 Feasibility and acceptability of electronic patient reported outcome measures in the routine care of people with inflammatory arthritis: Haywood Arthritis Portal study Rheumatology (IF 5.5) Pub Date : 2024-04-24 Natasha Cox, Chelsea Kettle, Haboo Wang, Shouma Dutta, Jon Packham, James Galloway, Jonathan Hill, Sara Muller, Samantha Hider, Zoe Paskins, Laurna Bullock, Ian C Scott
Background/Aims Electronic patient-reported outcome measures (ePROMs) assessing disease activity, function, pain, and quality of life can facilitate innovative inflammatory arthritis (IA) care, such as automating patient-initiated follow-up. This mixed-methods study evaluated whether their use is feasible and acceptable in routine care of people with inflammatory arthritis in an NHS setting. Methods
-
P160 High levels of CD19 expression is a characteristic feature of age-associated B cells in ageing and autoimmunity Rheumatology (IF 5.5) Pub Date : 2024-04-24 Kavina Shah, Vanessa Poon, Samuel J Taylor, Christian Klein, Florian Kollert, Franz Schuler, Sanjana Mathur, Madhura Castelino, Debajit Sen, Jo Cambridge, Mark Cragg, Maria Leandro, Arne Akbar, Venkat Reddy
Background/Aims Recent evidence implicates an important role for age-associated B cells (ABCs), defined as CD19+IgD-CD27-T-bet+ B cells, in healthy ageing, following viral infection and in active SLE. We know that co-receptors of the B cell receptor (BCR) such as CD19 and other activating receptors can influence B cell activation through distinct pathways. Therefore, we compared the expression of CD19
-
P001 An audit to assess whether patients who had a delayed or missed denosumab dose during the covid-19 pandemic came to any harm or suffered a subsequent fracture Rheumatology (IF 5.5) Pub Date : 2024-04-24 Sumaiya Rehman, Shabina Sultan
Background/Aims Denosumab is licensed by NICE for the secondary prevention of osteoporosis in patients who are unable to comply, have an intolerance, or contraindication to bisphosphonates. With the outbreak of Covid-19, denosumab appointments were delayed. A delay of denosumab doses by more than 16 weeks is associated with an increased risk of vertebral fractures. This audit was carried out to see
-
P153 Exploring the relationships between objective and subjective clinical measures in Sjogren's Syndrome Rheumatology (IF 5.5) Pub Date : 2024-04-24 Joe S Berry, Jessica Tarn, Dennis Lendrem, John Casement, Wan-Fai Ng
Background/Aims Patient Reported Outcome Measures (PROMs) are standardised, validated questionnaires designed to measure the patient’s perception of their disease. Discordance between the patient’s perspective and objective clinical measures (clinical scores, laboratory data) has led to increased interest in PROMs in Sjogren’s syndrome (SS). Initial concern about the subjectivity of PROMs has given
-
P036 Missing vital steps: why does my rheumatology team never speak to me about exercise? Rheumatology (IF 5.5) Pub Date : 2024-04-24 Ailsa M Bosworth, William J Gregory
Background/Aims UK Rheumatology services are stretched. Rollout of Patient Initiated Follow Up and pressure on job plans/clinic templates mean people with inflammatory arthritis (IA) may spend less time with their rheumatology team. An important but insufficient aspect of care in people with IA is empowering them to acquire good understanding of their disease and building their ability to deal effectively
-
P115 Thousands of rheumatoid arthritis & juvenile idiopathic arthritis patients benefit from interactive National Rheumatoid Arthritis Society broadcasts Rheumatology (IF 5.5) Pub Date : 2024-04-24 Clare B Jacklin
Background/Aims Pressures on NHS services results in many rheumatology patients missing out on vital information that can support them in understanding and managing their conditions. During the COVID pandemic, NRAS took to social media to host regular live interactive broadcasts to keep people informed on the latest regarding vaccines, staying safe and treatments etc. These proved such a successful
-
OA41 Exploring patterns of patient engagement with electronic patient reported outcome measures in inflammatory arthritis using latent class growth modelling Rheumatology (IF 5.5) Pub Date : 2024-04-24 Nikita Arumalla, Zijing Yang, Sam Norton, Melissa Crooks, Ayesha Khan, Rebecca Fitzgerald, Rory Gilligan, Emily Lindberg, Toktan Tabibi, Yik L Man, Sujith Subesinghe, James B Galloway, Toby Garrood
Background/Aims Routine collection of electronic patient reported outcome measures (ePROMs) can facilitate dynamic disease activity monitoring in patients with inflammatory arthritis (IA). In a real-world cohort of patients with IA, we describe patient characteristics associated with ever engaging with ePROMs, evaluate whether there are distinct groups of patients with similar engagement trajectories
-
E026 Severe odynophagia due to cricoarytenoid arthritis in a patient with rheumatoid arthritis and systemic lupus erythematosus Rheumatology (IF 5.5) Pub Date : 2024-04-24 Joe S Berry, John Robinson, Wan-Fai Ng
Background/Aims A 65-year-old man with a 20-year history of rheumatoid arthritis (RA) presented with dysphagia, odynophagia, polyarthralgia and significant weight loss. Methods - Results In addition to raised markers of inflammation, he was anti-nuclear antibody, anti-dsDNA antibody, anti-chromatin antibody and rheumatoid factor positive. He was initiated on 20mg once daily prednisolone but reported
-
OA30 Primary osteoarthritis chondrocyte map of chromatin conformation reveals novel effector genes Rheumatology (IF 5.5) Pub Date : 2024-04-24 Norbert Bittner, Chenfu Shi, Danyun Zhao, James Ding, Lorraine Southam, Diane Swift, Peter Kreitmaier, Mauro Tutino, Jenny Hankinson, Mark Wilkinson, Gisela Orozco, Eleftheria Zeggini
Background/Aims Osteoarthritis is a complex disease with a huge public health burden. Genome-wide association studies (GWAS) have identified hundreds of osteoarthritis-associated sequence variants, but the effector genes underpinning these signals remain largely elusive. Understanding chromosome organisation in 3D space is essential for identifying long-range contacts between distant genomic features
-
E054 Rituximab dose minimisation in rheumatoid arthritis, a retrospective outcome analysis Rheumatology (IF 5.5) Pub Date : 2024-04-24 Stephanie Butler, Helen Smith
Background/Aims Rituximab was originally developed as a non-Hodgkin lymphoma treatment and rheumatology adopted the same dosing for rheumatoid arthritis(RA); two 1000mg doses two weeks apart for each maintenance cycle. UHSussex utilises self-referral for maintenance rituximab dosing once disease control lessens. Evidence demonstrates patients treated with lower dose rituximab still enjoy good disease
-
P172 An integrated safety analysis of treatment-emergent fungal infections in patients with psoriasis, psoriatic arthritis, or axial spondyloarthritis treated with ixekizumab from 26 clinical studies Rheumatology (IF 5.5) Pub Date : 2024-04-24 Sergio Schwartzman, Luis Puig, Arnon D Cohen, Saakshi Khattri, Christian Jossart, Carlos Diaz, Alyssa Garrelts, Danting Zhu, Nadezhda Eberhart, Areti Eleftheriadi, Nithi Tangsirisap, Christopher Schuster, Alice B Gottlieb, Mohamed Sheesh
Background/Aims Interleukin (IL)-17 plays a role in host defense against common extracellular pathogens, including fungi. Treatment with IL-17 inhibitors has been associated with fungal infections. Ixekizumab (IXE) is an anti-IL-17A monoclonal antibody approved for the treatment of psoriasis (PsO) in adults and children, psoriatic arthritis (PsA) in adults, and axial spondyloarthritis (axSpA) in adults
-
P007 Successful use of patient initiated follow-up in a tertiary paediatric rheumatology service Rheumatology (IF 5.5) Pub Date : 2024-04-24 William Calvert, Jean Spinty, Liza J McCann, Gavin Cleary
Background/Aims Patient initiated follow-up (PIFU) is a national strategy enabling patients or carers to initiate contact with a service rather than a traditional model of routine scheduled appointments. PIFU enables patient empowerment and elective recovery after the Covid-19 pandemic. NHSE identified Paediatrics as appropriate for PIFU, but specific measures are needed to ensure safeguarding of paediatric
-
E023 Intimomedial mucoid degeneration. A rare vascular disease mimicking giant cell arteritis presentation Rheumatology (IF 5.5) Pub Date : 2024-04-24 Sarah Black, Maria Wray, Helen Stewart, Ellen Durkan, Viktor Serafimov, Philip Davey, Lisa Smith
Background/Aims The accuracy of giant cell arteritis (GCA) diagnosis has greatly improved in recent years with increasing use of fast track clinics and vascular ultrasound. The “halo” sign is recognised as confirmation of a positive test and is considered virtually pathognomonic of GCA in the setting of a correlating clinical presentation. There are caveats to this and “false halos” have been reported
-
E049 Including psychosocial approaches in paediatric and adolescent rheumatology: a service evaluation of an online art therapy group intervention for children, young people, and families Rheumatology (IF 5.5) Pub Date : 2024-04-24 Simon S Hackett, Sharmila Jandial, Lucy Craig, Patricia Watts
Background/Aims Children and young people with long-term physical conditions may develop mental health problems that have an impact upon their daily lives and families. Rates of anxiety and depression in children with juvenile idiopathic arthritis are higher than in peers without this diagnosis. The impact of long-term conditions on children and young people’s mental health and the pressure it puts
-
P183 Cognitive function in polymyalgia rheumatica Rheumatology (IF 5.5) Pub Date : 2024-04-24 Patricia Harkins, Sharon Cowley, Robert Harrington, David Kane, Richard Conway
Background/Aims Over the past decade our understanding of the prevalence, and indeed impact, of cognitive impairment in rheumatic diseases has increased. An aging population coupled with systemic inflammation have been postulated as key drivers of increased cognitive decline in these conditions. Intact cognitive function is imperative not only for quality of life and maintenance of one’s functional
-
E052 Characterising the factors associated with response to pain management in patients with the Stickler syndrome Rheumatology (IF 5.5) Pub Date : 2024-04-24 Rohan Mudkavi, Nicholas Shenker
Background/Aims The Stickler syndrome is associated with functional changes in one of the COL2 (type 1, common), COL11 (type 2, uncommon) or COL9 (very rare) genes and causes early onset osteoarthritis. Previous studies have looked at the factors associated with response to pain management interventions in osteoarthritis, but none have done so in a Stickler syndrome cohort. We aimed to identify the